Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estim...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham, Younes, Anas
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2016
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034737/
https://ncbi.nlm.nih.gov/pubmed/27432875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-02-699850
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items